Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Ependymoma and medulloblastoma tumoroids

New organoids offer deeper insights into pediatric brain cancer

Patient-derived organoids (PDOs), or tumoroids, for pediatric brain cancer show promise in helping researchers find new drugs and better understand the different responses of the tumor.

News • Dynamic in vitro platform

“Breathing” organoid offers new insights into lung disease

A new type of “breathing” lung organoid enables quantitative measurement of how easily the lung expands - and may provide a new way to study diseases such as pulmonary fibrosis.

News • Neurodegenerative diseases

New biomarker improves diagnosis of Parkinson's and LBD

A biomarker discovered in the cerebrospinal fluid could improve diagnosis of Parkinson's disease and dementia with Lewy bodies.

Related articles